ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease
The ESMO Congress 2025 has seen pivotal studies unveiling compelling evidence that a new class of…
Browsing: ESMO
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer
Results from a trial presented at ESMO 205 have shown that a targeted therapy combination improved…
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms
A multicenter Phase II clinical trial has demonstrated significant tumour shrinkage and disease control in patients…
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with…
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful…
ESMO 2025: Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
A drug that harnesses the immune system to attack cancer cells has proved successful in…
ESMO 2024: Breastfeeding after breast cancer is safe
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after…
ESMO 2024: Combination therapy reduced agitated delirium in patients with advanced cancers
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common…
ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer
Studies reported at ESMO 2024 have revealed new groups of women with early-stage (1) and…
ESMO 2024: Coaching programme for increased exercise in breast cancer patients
A study on exercise for cancer patients, presented at ESMO 2024, draws on data from…